Kairos Pharma, LTD. (KAPA) Institutional Ownership

Ownership Summary

A total of 13 institutions have reported a stake in Kairos Pharma, LTD. (NYSE:KAPA) as of December 2025, according to recent 13F filings with the SEC.

• Institutional ownership in Kairos Pharma edged up to 4.2% in December 2025, compared to 2.2% in September 2025.
• In percentage terms, this reflects as a holdings change of 130.56% quarter on quarter, and an increase of 116.67% year over year.
• Of these 13 institutional investors, 7 increased their holdings in Kairos Pharma, while 2 of them reduced positions, and 4 investors maintained their exposure.
• Collectively, institutional investors increased their stake in Kairos Pharma to 835.44K shares as of December 2025, a change that is up by 473.09K shares quarter on quarter and up 428.84K shares year over year.
• As of December 31, 2025, CITADEL ADVISORS LLC held Kairos Pharma's largest shareholding position with over 321.74K shares, representing 1.61% of total outstanding shares.
• Among the most significant buyers of Kairos Pharma during December 2025 were CITADEL ADVISORS LLC (321.74K), XTX Topco Ltd (48.49K), TWO SIGMA INVESTMENTS, LP (48.22K), HRT FINANCIAL LP (21.32K), TWO SIGMA ADVISERS, LP (15.14K).
• Leading sellers of Kairos Pharma stock in December 2025 included Tower Research Capital LLC (TRC) (1.73K), BANK OF AMERICA CORP /DE/ (170).
• The top 10 institutional holders of Kairos Pharma for the quarter ending December 2025 included CITADEL ADVISORS LLC (321.74K), VANGUARD GROUP INC (131.83K), TWO SIGMA INVESTMENTS, LP (94.01K), GEODE CAPITAL MANAGEMENT, LLC (72.83K), XTX Topco Ltd (48.49K), SevenBridge Financial Group, LLC (44.29K), Aptus Capital Advisors, LLC (44.29K), STATE STREET CORP (24.10K), HRT FINANCIAL LP (21.32K), TWO SIGMA ADVISERS, LP (15.14K).